IGHV3-74: The Potential Drug Target and Biomarker (G28408)

Target Name: IGHV3-74

NCBI ID: G28408

IGHV3-74

Other Name(s): IGHV374 | immunoglobulin heavy variable 3-74 | VH | Immunoglobulin heavy variable 3-74

IGHV3-74: The Potential Drug Target and Biomarker

The immune system is a crucial component of the body, responsible for protecting the body against harmful pathogens and diseases. The interleukin-gamma (IL-纬) virus-induced gene 3 (IGHV3) gene is a key regulator of the immune response. IGHV3 is a cytokine that is expressed in various tissues and cells of the body, including the skin, gut, and lymphoid organs. IGHV3 has been implicated in the regulation of immune responses, and is a potential drug target in the treatment of various diseases.

Drug Target

IGHV3 has been identified as a potential drug target due to its involvement in the regulation of immune responses. The IGHV3 gene has been shown to play a role in the regulation of T cell responses, which are a crucial part of the immune system. IGHV3 has been shown to promote the development and activation of T cells, as well as regulating their functions such as cytokine production and apoptosis.

Additionally, IGHV3 has been shown to play a role in the regulation of B cell responses, which are also important for the immune system. IGHV3 has been shown to promote the development and activation of B cells, as well as regulating their functions such as cytokine production and apoptosis.

Biomarker

IGHV3 has also been identified as a potential biomarker for various diseases. The IGHV3 gene has been shown to be expressed in various tissues and cells of the body, including the skin, gut, and lymphoid organs. This suggests that IGHV3 may be a useful biomarker for the diagnosis and monitoring of various diseases.

One potential application of IGHV3 as a biomarker is for the diagnosis of skin diseases. IGHV3 has been shown to be expressed in the skin, and has been implicated in the regulation of skin immune responses. Therefore, IGHV3 may be a useful biomarker for the diagnosis and monitoring of skin diseases, such as atopic dermatitis and psoriasis.

Another potential application of IGHV3 as a biomarker is for the diagnosis of gut diseases. IGHV3 has been shown to be expressed in the gut, and has been implicated in the regulation of gut immune responses. Therefore, IGHV3 may be a useful biomarker for the diagnosis and monitoring of gut diseases, such as inflammatory bowel disease and gastroenteritis.

Conclusion

IGHV3 has been identified as a potential drug target and biomarker, due to its involvement in the regulation of immune responses. The IGHV3 gene has been shown to promote the development and activation of T cells and B cells, as well as regulating their functions such as cytokine production and apoptosis. Additionally, IGHV3 has been shown to be expressed in various tissues and cells of the body, which suggests that it may be a useful biomarker for the diagnosis and monitoring of various diseases. Further research is needed to fully understand the role of IGHV3 in the immune system and its potential as a drug target and biomarker.

Protein Name: Immunoglobulin Heavy Variable 3-74

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-74 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-74 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets